An IPO, or initial public offering, is a company's first sale of shares to public investors. As MarketBeat puts it in its IPO calendar primer, the offering can raise capital to fund growth, repay debt, or pursue other business priorities. The popular assumption is that going public is a victory lap. In practice, it is a negotiation over price, a marketing campaign, and a set of trading restrictions, all compressed into a few months.
The negotiation matters more than the ceremony. An announced IPO is a moving target: timing, pricing, and other terms can change before shares ever reach the public market, per MarketBeat's calendar guidance. Recent listings show how wide the outcomes run. Stock Analysis's tracker of the 200 most recent IPOs lists Vogenx at a $13.00 offer against a later price of $19.08, while ITG, Inc. priced at $16.00 and later traded at $4.93. Same process, opposite results.
This piece walks through the machinery: who sells, how the price gets set, what the roadshow is for, and what the lockup period does to the stock afterward. For readers tracking the wider economy, newly public companies also feed into market indexes and earnings season, which is where IPO mechanics connect to business news more broadly.
What is an IPO, exactly?
An IPO is the transaction that converts a privately held company into one with publicly traded shares. The company (or, in some deals, early shareholders) sells a block of stock to institutional and retail investors through underwriting banks, and the shares then trade on an exchange under a new ticker.
Three features define the event. First, it is typically the company's first public sale of shares, per MarketBeat's definition. Second, the terms are provisional until the last moment; MarketBeat notes that timing, pricing, and other offering terms can change before the shares list. Third, the money is real and earmarked: growth capital, debt repayment, or other corporate priorities, again per MarketBeat. A listing that raises no primary cash for the company, where only existing holders sell, is a different animal and worth checking in any prospectus.
How is the IPO price actually set?
The price is set by the underwriters, the banks running the deal, after they gauge demand from large investors. The mechanics follow a rough sequence:
- The company files a registration statement describing its business, financials, and risks.
- The underwriters propose a price range and take the management team on a roadshow to pitch institutional investors.
- Those investors indicate how many shares they would buy at prices inside the range.
- The night before listing, the deal is priced, often above, inside, or below the original range depending on the order book.
- Shares begin trading, and the first trade price is set by supply and demand, not by the offering price.
The gap between the offering price and the first trade is the famous "pop," and it cuts both ways. A big pop rewards the clients who got allocation but means the company sold shares cheaper than the market would have paid. A flat or negative debut suggests the banks priced the deal at, or above, what buyers would bear.
The record from recent listings is unkind to any single narrative. Stock Analysis's tracker shows City Therapeutics priced at $18.00 and later quoted at $20.77, while Accelevation Holdings priced at $18.00 and stood at $12.25. Electra Therapeutics went out at $15.00 and later traded at $9.25. The offering price is an estimate, not a verdict.
What does the roadshow actually do?
The roadshow is a pre-sale. Management travels to meet institutional investors, presents the same disclosure that appears in the registration statement, and answers questions the written document cannot. Underwriters use those meetings to build the order book: who wants in, at what size, at what price.
A concrete recent deal shows the outputs. According to The Online Investor's IPO tracker, City Therapeutics, Inc. (Nasdaq: CTY), a clinical-stage biotechnology company developing RNA interference therapeutics, priced an upsized offering of 11,111,111 shares at $18.00 per share, with expected gross proceeds to the company of approximately $200.0 million before underwriting discounts and expenses. The underwriters also received a 30-day option to purchase up to an additional 1,666,666 shares at the offering price.
That last item is a standard piece of plumbing worth knowing. The over-allotment option lets underwriters cover strong demand or stabilize early trading by selling or buying extra shares. It is one of several levers, alongside the pricing decision itself, that determine whether the first days of trading look orderly or chaotic.
What is the lockup period, and why does it matter?
The lockup period is a contractual window after the IPO during which insiders and early investors, founders, employees with vested shares, venture funds, agreed not to sell. It exists to prevent a flood of supply from crushing the price in the weeks after listing, while the market is still forming a view of the company.
The analysis: the lockup's expiry is a scheduled supply event, and the record of recent deals explains why investors watch it. When the window opens, the tradable float can expand sharply, and holders who have waited years for liquidity finally have theirs. Whether the stock falls depends on how much stock insiders actually intend to sell and how the company's reported performance is trending, neither of which the lockup date itself reveals. What would change this reading is a deal structure that staggers insider sales or waives the lockup early, which some underwriters do; the calendar date alone is a weak signal.
For a company's own treasury, the IPO is only the first of many capital-markets decisions. Later ones, such as repurchasing shares, follow their own rulebook, as covered in How Share Buybacks Work — and Why Regulators Watch Them.
Who wins and who loses on IPO day?
The sourced record supports a cautious answer: it depends on which side of the pricing you sit. Companies that priced high and traded lower afterward, like Electra Therapeutics at $15.00 offering versus $9.25 later per Stock Analysis's tracker, left buyers with losses. Companies that priced and then traded well above the offer, like Vogenx at $13.00 against $19.08, left allocated buyers with gains and, arguably, left the company money on the table.
The analysis: the recurring pattern in the tracker is dispersion, not direction. Recent listings include SPAC-related shells holding near their $10.00 offers, biotechs up and down by double digits, and names like Bending Spoons at a $29.00 offer against $45.69 later. There is no reliable IPO-day trade in this data. What the record does establish is that the offering price is a negotiated estimate, and the market's own price forms within days. Readers should treat any single debut, hot or cold, as one data point rather than a signal about the market.
What should a reader take away from the IPO pipeline?
The evidence here establishes three things. An IPO is a company's first public share sale, designed to raise capital, per MarketBeat. Its terms stay fluid until pricing night, and the deal is marketed through a roadshow that produces a priced order book, as the City Therapeutics offering illustrates. And outcomes vary widely: Stock Analysis's tracker of recent listings shows later prices ranging from $0.941 on a $5.00 offer to $45.69 on a $29.00 offer.
What remains unknown in any individual deal is how the stock will trade after the lockup expires and whether the company converts its raised capital into reported earnings. Those questions are answered later, in quarterly results, which is where IPO coverage connects to What Earnings Guidance Tells Investors — and What It Doesn't and, eventually, to index inclusion decisions described in How Stock Index Committees Pick Their Companies. The IPO is the entrance. Everything that matters happens after it.
